TY - JOUR
T1 - Vitamin K-2-MK-7 improves nitric oxide-dependent endothelial function in ApoE/LDLR-/- mice
AU - Bar, Anna
AU - Kus, Kamil
AU - Manterys, Angelika
AU - Proniewski, Bartosz
AU - Sternak, Magdalena
AU - Przyborowski, Kamil
AU - Moorlag, Martijn
AU - Sitek, Barbara
AU - Marczyk, Brygida
AU - Jasztal, Agnieszka
AU - Skorka, Tomasz
AU - Franczyk-Zarow, Magdalena
AU - Kostogrys, Renata B.
AU - Chlopicki, Stefan
PY - 2019
Y1 - 2019
N2 - Although, vitamin K-2 displays vasoprotective effects, it is still not known whether K-2 treatment improves endothelial function.In ApoE/LDLR-/- mice at the stage prior to atherosclerosis development, four-week treatment with K-2-MK-7, given at a low dose (0.05 mg/kg), improved acetylcholine- and flow-induced, endothelium-dependent vasodilation in aorta or in femoral artery, as assessed by MRI in vivo. This effect was associated with an increased NO production, as evidenced by EPR measurements in ex vivo aorta. Treatment with higher doses of K-2-MK-7 (0.5; 5 mg/kg) resulted in a dose-dependent increase in plasma K-2-MK-7 and K-2-MK-4 concentration, without further improvement in endothelial function. In ApoE/LDLR-/- mice with developed atherosclerotic plaques, treatment with a low (0.03 mg/kg) or high (10 mg/kg) dose of K-2-MK-7 resulted in a similar degree of endothelium-dependent vasodilation improvement and increase in plasma nitrate concentration, what was not associated with changes in thrombin generation as measured by CAT. Both doses of K-2-MK-7 also reduced media thickness in the brachiocephalic artery, but did not modify atherosclerotic plaque size.In conclusion, K-2-MK-7 improves NO-dependent endothelial function in ApoE/LDLR-/- mice. This study, identifies the endothelial profile of the pharmacological activity of vitamin K-2, which has not been previously described.
AB - Although, vitamin K-2 displays vasoprotective effects, it is still not known whether K-2 treatment improves endothelial function.In ApoE/LDLR-/- mice at the stage prior to atherosclerosis development, four-week treatment with K-2-MK-7, given at a low dose (0.05 mg/kg), improved acetylcholine- and flow-induced, endothelium-dependent vasodilation in aorta or in femoral artery, as assessed by MRI in vivo. This effect was associated with an increased NO production, as evidenced by EPR measurements in ex vivo aorta. Treatment with higher doses of K-2-MK-7 (0.5; 5 mg/kg) resulted in a dose-dependent increase in plasma K-2-MK-7 and K-2-MK-4 concentration, without further improvement in endothelial function. In ApoE/LDLR-/- mice with developed atherosclerotic plaques, treatment with a low (0.03 mg/kg) or high (10 mg/kg) dose of K-2-MK-7 resulted in a similar degree of endothelium-dependent vasodilation improvement and increase in plasma nitrate concentration, what was not associated with changes in thrombin generation as measured by CAT. Both doses of K-2-MK-7 also reduced media thickness in the brachiocephalic artery, but did not modify atherosclerotic plaque size.In conclusion, K-2-MK-7 improves NO-dependent endothelial function in ApoE/LDLR-/- mice. This study, identifies the endothelial profile of the pharmacological activity of vitamin K-2, which has not been previously described.
KW - Endothelial function
KW - Atherosclerosis
KW - MRI
KW - Menaquinone-7
KW - DENSITY-LIPOPROTEIN RECEPTOR
KW - GAMMA-CARBOXYGLUTAMIC ACID
KW - VASCULAR CALCIFICATION
KW - THROMBIN GENERATION
KW - ARTERIAL STIFFNESS
KW - LOW CARBOHYDRATE
KW - DOUBLE-BLIND
KW - ATHEROSCLEROSIS
KW - SUPPLEMENTATION
KW - DYSFUNCTION
U2 - 10.1016/j.vph.2019.106581
DO - 10.1016/j.vph.2019.106581
M3 - Article
C2 - 31421222
VL - 122-123
JO - Vascular Pharmacology
JF - Vascular Pharmacology
SN - 1537-1891
M1 - 106581
ER -